How often does Akebia Therapeutics move more than the options market prices?

1 of the last 8 reports moved at least as far as the implied move.

AKBANasdaqPharmaceutical Preparations

Akebia Therapeutics, Inc. (AKBA) earnings date, market-implied expected move, and options open interest by expiry

0.46

−0.24 · −34.49%

Regular session13:13 ET

Open0.63Volume10.8MMkt cap$192.5MEPS-0.11

Day0.45 – 0.631%52-wk0.54 – 2.130%

AKBA

Akebia Therapeutics, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

Feb 25

before open · in 112 days

est.Q4 FY26

Calendar

Next report

Last report

Nov 5

before open

confirmedQ3 FY26Nov 4 close

Implied vs realized

Linked news

1hCAH · supplierWe're raising our price target on Cardinal Health after another stellar quarter of profits
5hCYCN · supplierCyclerion Therapeutics reports net loss of $46,425 thousand; cash $456,221 thousand
1dQTTB · supplierQ32 Bio posts net loss of $8,922 thousand for Q3; cash $289,587 thousand

News

Largest filed tie

13F top-10 QoQ

+17.66%

shares held · 10 largest managers

13F · Jun 30 '26128d lag

170 managers

Top fund weight

0.01%

AKBA weight · IWM

N-PORTJun 30 '26

3 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Akebia Therapeutics (AKBA) is expected to report on Feb 25 before open (estimated date).

Implied vs realized

8 reports

1 of 8≥ implied

avg implied: ±20.7%
avg realized: ±15.0%

Nov 7 '24Nov 7 '24confirmed±10.6%▼−6.75%×0.64

Mar 13 '25Mar 13 '25confirmed±14.7%▼−12.44%×0.84

May 8 '25May 8 '25confirmed±12.4%▲+6.50%×0.52

Aug 7 '25Aug 7 '25confirmed±30.2%▼−20.48%×0.68

Q3 FY25Nov 10 '25confirmed±20.4%▼−18.14%×0.89

Q1 FY26Feb 26 '26confirmed±27.1%▲+9.09%×0.34

May 7 '26May 7 '26confirmed±14.2%▼−20.27%×1.43

Q2 FY26Aug 5 '26confirmed±35.9%▼−26.02%×0.73

quarterimplied−40%0+40%realized×

Q2 FY26±35.9%▼−26.02%×0.73

May '26±14.2%

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 4 expiries · Nov 3 close

0.60OI · 4 expiries · Nov 3 closeP/C open interest · Apr 16 · first expiry after the report

PUTS · chgexpiry · days · P/CCALLS · chgP/C

130%Nov 2015d0.04341−9%0.04

1100%Dec 1843d0.11961−3%0.11

3,1990%Jan 1571d0.2015,8060%0.20

report · Feb 25 · before open · est.

5050%Apr 16162d837+3%

ExpiryPutsCallsP/C

Nov 2015d130%341−9%0.04

Dec 1843d1100%961−3%0.11

Jan 1571d3,1990%15,8060%0.20

report · Feb 25 · before open · est.

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

No implied move.

Linked exposure

Revenue flow

as filedQ3 FY26

−38.90%as filednet margin · revenue −24.88% QoQ · −37.20% YoY

Revenue$37M−24.88%

Gross profit$31M82.76%−21.09%

Operating income−$11M−31.06%−81.19%

Pre-tax income−$14M−60.43%

Net income−$14M−38.90%−61.14%

Cost of revenue$6M−38.97%

Operating expenses$42M−6.72%

Tax$175,000+150.00%

Other expense−$3M−8.16%

Source: SEC filings · standardized · QE Sep 30 '26 · bars = % of revenue

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 13:00 ET

Intraday

Event sensitivity

FOMC ×1.41· ±4.6% vs ±3.3% · 24 releases

eventrelease day|move|up · n×base

FOMCrate decision±4.6%14 of 24×1.41

CPIconsumer prices±3.1%6 of 10×0.95

CPROFcorporate profits±2.8%7 of 12×0.84

GDPgross domestic product±2.7%12 of 19×0.82

NFPjobs report±2.6%5 of 10×0.79

PCEpersonal income & outlays±2.4%11 of 19×0.72

PPIproducer prices±2.1%2 of 10×0.64

Bar = avg |move| to ±5% · tick = ±3.3% avg day · ×base = |move| ÷ ±3.3% · min 6 releases

Earnings history

EPS -0.05 · consensus —

Quarter	Reported	EPS	Consensus
Q3 FY26	—	-0.05	—
Q2 FY26	Aug 5 '26 · confirmed	-0.03	—
Q1 FY26	Feb 26 '26 · confirmed	-0.03	—
Q3 FY25	Nov 10 '25 · confirmed	0.00	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod